GlassScriptPhysician profile
Matthew Aaron Vickers
NPI 1013494566
$6,266.80
in general payments reported to CMS, 2019-2025
27 companies · $801 in 2025
The $801 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,337 · 2022: $1,427 · 2023: $1,145 · 2024: $557 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,332.96 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $699.50 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $562.19 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $465.59 | 2021-2024 | Caplyta |
| Ironshore Pharmaceuticals INC. | $399.94 | 2021-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $390.88 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $359.66 | 2021-2025 | Rexulti |
| Corium, LLC | $265.77 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $243.42 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $208.88 | 2021-2023 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $194.01 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.23 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $157.33 | 2022-2023 | Ingrezza |
| Bausch Health US, LLC | $123.57 | 2021-2023 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $111.62 | 2024-2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $111.42 | 2021-2024 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $69.58 | 2021-2025 | Austedo Xr, Austedo Xr |
| Neos Therapeutics, LP | $67.97 | 2021-2024 | Cotempla Xr-Odt |
| Jazz Pharmaceuticals INC. | $64.79 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $60.83 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $43.40 | 2021-2023 | Belsomra |
| Adlon Therapeutics L.P. | $37.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.71 | 2023 | Quviviq |
| Almatica Pharma LLC | $28.82 | 2022 | |
| Indivior INC. | $27.42 | 2023 | Perseris |
| Vanda Pharmaceuticals INC. | $23.63 | 2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $14.48 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.